S100A2 and pancreatic ductal adenocarcinoma: EOPC demonstrated enrichment of genes associated with more aggressive molecular pathology and the squamous (basal-like) molecular subtype of pancreatic ductal adenocarcinoma, including S100A2 (P < 0.001) and TP63 (P = 0.044), and down-regulation of GATA6 (P = 0.016).<h4>Conclusion</h4>EOPC is associated with a shorter time to recurrence and more aggressive, adverse molecular pathology.